Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million

HANGZHOU, China, March 28, 2025 /PRNewswire/ -- On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4 million, a year-on-year increase of 48.3%, and achieved a net profit exceeding USD 14 million, marking its first full-year profitability.

Amid a dynamic market environment, Zylox-Tonbridge benefited from the economies of scale driven by sustained revenue growth, entering a new phase of sustainable profitability. This fully demonstrates the Company's robust capabilities in developing comprehensive product solutions, delivering high-quality products, and operating efficiently. Looking ahead, Zylox-Tonbridge remains committed to its mission of "Innovation for Quality Life", focusing on advancements in medical technology to improve high-quality healthcare and drive the Company's long term growth.

Strong Performance in Centralized Procurement and Continued Overseas Expansion

In 2024, the Company actively seized opportunities in centralized procurement, securing successful multiple bids by leveraging its robust and high-quality product portfolio. These achievements are expected to accelerate product penetration in hospitals and enhance market competitiveness, laying a solid foundation for sustained growth.

In the "3+N" provincial alliance centralized procurement led by Hebei, our SilverSnake Intracranial Support Catheter fully demonstrated its advantages in the A group for its respective category, winning the bid with the highest ranking. During the national-level venous stent procurement, the ZYLOX Penguin Peripheral Venous Stent System became the only domestic bidder to win the first rule ...